ArticleBritish journal of cancer2017

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.

Cassandre Yip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.